Company intelligence / Profile preview

Kinoxis Therapeutics

Camberwell, Victoria, Australiakinoxistherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

KNX100 has completed Phase 1 clinical trials and is advancing to Phase 2a for treating agitation associated with dementia (CARES-X study). The company also secured a partnership with Boehringer Ingelheim worth up to $273 million to develop oxytocin-targeting precision treatments.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

KNX100

3 more assets in the full pipeline.

Request access →

Partnerships

Boehringer Ingelheim ($273 million partnership announced in May 2023)

Beyond the preview

Go deeper on Kinoxis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinoxis Therapeutics.

Explore the full profile